Abiopharma

🔍 CASPER MARC N (Director)

Company: THERMO FISHER SCIENTIFIC INC. (TMO)

Report Date: 2026-03-05

Detailed Transactions and Holdings:

• Acquired 4,000 shares of Common Stock at $309.63 per share (Direct)
  Date: 2026-03-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 127,925.36 | transaction_form_type: 4
• Sold 20 shares of Common Stock at $503.66 per share (Direct)
  Date: 2026-03-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 127,905.36 | transaction_form_type: 4 | Footnotes: F1
• Sold 60 shares of Common Stock at $505.76 per share (Direct)
  Date: 2026-03-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 127,845.36 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 58 shares of Common Stock at $507.54 per share (Direct)
  Date: 2026-03-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 127,787.36 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 99 shares of Common Stock at $509.66 per share (Direct)
  Date: 2026-03-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 127,688.36 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 214 shares of Common Stock at $511.78 per share (Direct)
  Date: 2026-03-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 127,474.36 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 411 shares of Common Stock at $512.73 per share (Direct)
  Date: 2026-03-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 127,063.36 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 1,133 shares of Common Stock at $513.71 per share (Direct)
  Date: 2026-03-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 125,930.36 | transaction_form_type: 4 | Footnotes: F1, F7
• Sold 570 shares of Common Stock at $514.71 per share (Direct)
  Date: 2026-03-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 125,360.36 | transaction_form_type: 4 | Footnotes: F1, F8
• Sold 348 shares of Common Stock at $515.64 per share (Direct)
  Date: 2026-03-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 125,012.36 | transaction_form_type: 4 | Footnotes: F1, F9
• Sold 201 shares of Common Stock at $516.73 per share (Direct)
  Date: 2026-03-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 124,811.36 | transaction_form_type: 4 | Footnotes: F1, F10
• Sold 106 shares of Common Stock at $517.83 per share (Direct)
  Date: 2026-03-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 124,705.36 | transaction_form_type: 4 | Footnotes: F1, F11
• Sold 516 shares of Common Stock at $519.13 per share (Direct)
  Date: 2026-03-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 124,189.36 | transaction_form_type: 4 | Footnotes: F1, F12
• Sold 264 shares of Common Stock at $519.74 per share (Direct)
  Date: 2026-03-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 123,925.36 | transaction_form_type: 4 | Footnotes: F1, F13
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-05 | Code: H | nature_of_ownership: By Alison Casper 2020 Irrevocable Trust | shares_owned_after: 11,300.00 | Footnotes: F14
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-05 | Code: H | nature_of_ownership: By Floral Park Associates, Inc. | shares_owned_after: 14,608.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-05 | Code: H | nature_of_ownership: By MNC 2020 Irrevocable Trust | shares_owned_after: 5,000.00 | Footnotes: F15
• Sold 4,000 shares of Stock Option (Right to Buy) at $309.63 per share (Derivative)
  Date: 2026-03-05 | Code: M | Expires: 2027-02-25 | equity_swap_involved: 0 | shares_owned_after: 40,550.00 | transaction_form_type: 4 | Footnotes: F16

Footnotes:

• F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2025.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $505.36 to $506.16, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $507.40 to $508.12, inclusive.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $509.63 to $509.76, inclusive.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $511.21 to $512.18, inclusive.
• F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $512.23 to $513.22, inclusive.
• F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $513.27 to $514.24, inclusive.
• F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $514.28 to $515.24, inclusive.
• F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $515.30 to $516.00, inclusive.
• F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $516.47 to $517.07, inclusive.
• F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $517.60 to $518.16, inclusive.
• F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $518.62 to $519.57, inclusive.
• F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $519.62 to $519.91, inclusive.
• F14: The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein.
• F15: The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein.
• F16: The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024.